Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mRNA-transfected dendritic cell vaccine (Inge Marie Svane)
- Development stage
- Unknown
- Lead developer
- Center for Cancer Immune Therapy
- Modality
- Vaccines & Immunotherapeutics, Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intradermal
01
Overview
mRNA-transfected dendritic cell vaccine (Inge Marie Svane) is an autologous cell-based cancer immunotherapy developed for the treatment of metastatic castration-resistant prostate cancer (mCRPC). The vaccine is produced by harvesting a patient's monocytes via leukapheresis, which are then matured ex vivo into dendritic cells using a cytokine cocktail including GM-CSF, IL-4, IL-1β, TNFα, IL-6, and PGE2. These mature dendritic cells are subsequently transfected with messenger RNA (mRNA) encoding four specific tumor-associated antigens: Prostate-Specific Antigen (PSA), Prostatic Acid Phosphatase (PAP), survivin, and human Telomerase Reverse Transcriptase (hTERT). Once administered intradermally, these dendritic cells present the antigens to the patient's immune system to stimulate a targeted T-cell response against prostate cancer cells. This therapeutic approach has been investigated in Phase II clinical trials, often in combination with standard chemotherapy such as docetaxel, to evaluate its ability to induce immune responses and improve clinical outcomes in patients with advanced prostate cancer.
- Other names
- mRNA transfected dendritic cellDCvacPSA/PAP/survivin/hTERT mRNA-transfected dendritic cell vaccinemRNA-transfected DC vaccineDC vaccine (Svane)
02
Targets
BIRC5 (Survivin)TERT (Telomerase)PAP (Prostatic acid phosphatase)PSA (Puromycin-sensitive aminopeptidase)
Beyond the preview
Go deeper on mRNA-transfected dendritic cell vaccine (Inge Marie Svane).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mRNA-transfected dendritic cell vaccine (Inge Marie Svane).